As a useful prescription for type 2 diabetes, the action of DPP-4 is based on inhibiting the degradation of type 1 glucagon-like peptide (GLP-1), an incretin stimulates the glucose-dependent insulin secretion of β cells. Here, INS is linked to type 2 diabetes mellitus.